Pulmonary Artery Banding — Palliative Cardiac Surgery for Congenital Heart Disease — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pulmonary artery banding (PAB) is a palliative cardiac surgical procedure used in infants with congenital heart defects that cause excessive pulmonary blood flow (left-to-right shunting). By placing a constricting band around the main pulmonary artery, the surgeon reduces the volume and pressure of blood entering the pulmonary circulation, protecting the pulmonary vasculature from the irreversible obstructive changes of pulmonary hypertension and preventing the haemodynamic consequence of high-output cardiac failure.

The technique was first described by Muller and Dammann in 1952 as a temporising measure for patients with large ventricular septal defects (VSDs) who were too small, sick, or anatomically complex for immediate complete intracardiac repair. In contemporary practice, PAB is typically a staged strategy: the band is placed in infancy to stabilise the infant, and then definitively removed at the time of complete intracardiac repair — usually 3–6 months later when the child has grown, pulmonary vascular resistance has stabilised, and the surgical team has fully characterised the cardiac anatomy.

The FloWatch-PAB system (EndoArt SA, Lausanne) represents a major advance: a totally implantable device with an electrically-adjustable band that can be tightened or loosened transcutaneously using an external electromagnetic activator, avoiding repeated surgical revision for band adjustment. FloWatch allows precise haemodynamic titration without reoperation and is increasingly used in single-ventricle and borderline biventricular repair strategies.

PAB is performed through a left lateral thoracotomy or median sternotomy without cardiopulmonary bypass in most cases, typically in a cardiac intensive care setting. The band is positioned around the main pulmonary artery, tightened until the distal pulmonary artery pressure is reduced to approximately one-third to one-half of systemic pressure, and secured in place.

Pulmonary artery banding is applied across a spectrum of congenital cardiac lesions characterised by large left-to-right shunting and pulmonary overcirculation that cannot be immediately corrected by complete intracardiac repair due to patient size, complexity, or associated co-morbidities.

• Large ventricular septal defect (VSD): The most common historical indication. Unrestrictive VSDs allow unrestricted left-to-right shunting, causing high pulmonary blood flow, pulmonary hypertension, failure to thrive, and recurrent respiratory infections in infancy. PAB was the standard bridge to repair before the advent of neonatal cardiopulmonary bypass. In modern practice, primary VSD closure is preferred at 3–6 months, but PAB remains used in very premature infants, those with additional comorbidities, or multiple muscular VSDs ("Swiss cheese" VSDs).
• Complete atrioventricular septal defect (AVSD or CAVC): Particularly in infants with Down syndrome, associated medical problems, or very early presentation with pulmonary hypertension before the typical repair window of 3–6 months. PAB protects the pulmonary vasculature while the infant is optimised for complete repair.
• Single ventricle physiology: In hearts with a dominant ventricle and a rudimentary contralateral chamber (e.g., tricuspid atresia, unbalanced AVSD, double-inlet left ventricle), PAB controls pulmonary blood flow to achieve appropriate arterial oxygen saturations (typically 75–85%) and prevents volume overloading of the single working ventricle, preparing it for the staged Fontan palliation pathway.
• Hypoplastic left heart syndrome (HLHS) — Hybrid Stage I: In centres using the hybrid approach as an alternative to the Norwood Stage I operation, bilateral PAB of both branch pulmonary arteries is combined with ductal stenting and atrial septostomy. This avoids cardiopulmonary bypass in the neonatal period and is followed by a comprehensive Stage II procedure at 3–6 months.
• Complex CHD with multiple defects: Conditions such as double-outlet right ventricle (DORV), transposition of the great arteries with VSD, or multiple muscular VSDs where complete repair is deferred may all be managed with PAB as a temporising strategy.

Patient selection for pulmonary artery banding requires detailed echocardiographic and haemodynamic assessment by a specialist paediatric cardiologist and congenital cardiac surgeon. The decision to band versus proceed directly to complete repair is influenced by multiple anatomical and physiological factors.

• Patient size and weight: Infants below 2.5–3.0 kg represent significantly increased risk for cardiopulmonary bypass. PAB allows cardiac stabilisation and growth before definitive surgery. Many centres set 5–6 kg as the weight target for complete VSD closure following banding.
• Haemodynamic severity of pulmonary overcirculation: Significant pulmonary hypertension (Qp:Qs above 2:1 on catheterisation), high pulmonary artery pressure (above two-thirds systemic), and evidence of volume overload with poor ventricular function support early banding to prevent irreversible pulmonary vascular disease (Eisenmenger syndrome).
• Anatomical complexity precluding immediate repair: Multiple muscular VSDs requiring extensive intracardiac reconstruction, complex AVSD variants, or lesions requiring biventricular conversion of borderline left ventricular size all benefit from a staged approach with PAB.
• Single ventricle pathway planning: In functionally univentricular hearts, PAB forms part of a planned staged palliation (Norwood/Glenn/Fontan or hybrid pathway) and is an integral component of a pre-determined surgical strategy rather than an emergency intervention.
• Significant medical comorbidities: Pulmonary disease, prematurity, chromosomal anomalies (notably Down syndrome with AVSD), or concurrent non-cardiac conditions may defer complete repair. PAB allows haemodynamic stabilisation while comorbidities are addressed.

Contraindications to PAB include severe pulmonary valve stenosis (band would excessively restrict already limited flow), pulmonary atresia, or conditions where pulmonary blood flow augmentation rather than restriction is required. The anatomy must be compatible with subsequent band removal and definitive repair.

The technical execution of pulmonary artery banding and the broader surgical strategy differ depending on cardiac anatomy, centre experience, and planned palliation pathway.

• Standard fixed-band PAB (thoracotomy or sternotomy): A silastic or umbilical tape band is passed around the main pulmonary artery and tightened to achieve target haemodynamics — typically a distal pulmonary artery pressure of one-third to one-half of systemic, or an arterial oxygen saturation of 80–85% in single-ventricle physiology. The band is ligated with silk sutures and the diameter confirmed by direct measurement. This approach does not require cardiopulmonary bypass.
• FloWatch adjustable PAB: An implantable electromechanically adjustable band positioned around the main pulmonary artery, connected to a subcutaneous antenna. The band can be tightened or released transcutaneously using an external electromagnetic device without reoperation. Particularly valuable in borderline biventricular repair cases where precise titration of pulmonary flow is essential for left ventricular training, and in remote or resource-limited settings where surgical revision for band adjustment carries prohibitive risk.
• Hybrid Stage I for HLHS: Bilateral branch pulmonary artery banding (right and left PAs separately) is combined with ductal stenting via catheterisation and balloon atrial septostomy. This avoids neonatal cardiopulmonary bypass entirely. The comprehensive Stage II procedure — combining reverse PA banding (de-banding) with Glenn anastomosis and aortic arch reconstruction — is performed at 3–6 months of age.
• DeBanding with complete intracardiac repair: At the planned interval (typically 3–6 months post-banding), the PAB is removed at the time of complete repair under cardiopulmonary bypass. The pulmonary artery at the band site may require a pericardial patch if the band has caused significant distortion or stenosis. This is standard for VSD closure, AVSD repair, and DORV correction.
• Primary complete repair (no banding): In experienced neonatal cardiac surgery centres, many lesions (including large VSDs and complete AVSDs in infants above 3 kg) are repaired primarily without prior banding. PAB is therefore reserved for specific indications rather than applied universally.

Pulmonary artery banding achieves several critical haemodynamic and protective goals that justify its continued use in specific congenital cardiac anatomies.

• Protection of pulmonary vasculature: The primary benefit of PAB is preventing the development of irreversible pulmonary vascular obstructive disease (Eisenmenger physiology). In unrepaired large left-to-right shunts, chronic exposure of the pulmonary vasculature to high pressure and high flow causes progressive medial hypertrophy, intimal proliferation, and ultimately thrombotic and plexiform changes that are irreversible. PAB normalises pulmonary artery pressure and flow, preserving vascular reactivity and operability.
• Haemodynamic stabilisation for high-risk infants: For very small, premature, or medically compromised infants, PAB allows cardiac failure and pulmonary symptoms to be controlled without the risks of neonatal cardiopulmonary bypass. Weight gain, neurological maturation, and medical optimisation can proceed before complete repair at a safer weight and age.
• Enables staged single-ventricle palliation: In univentricular physiology, PAB is an integral component of the Fontan palliation pathway, achieving controlled pulmonary blood flow and appropriate arterial saturations (SpO2 75–85%) during the inter-stage period between birth and the cavopulmonary connection (Glenn anastomosis).
• Left ventricular retraining: In patients with transposition of the great arteries who have undergone prior atrial switch (Mustard/Senning) and require conversion to an arterial switch, PAB is used to retrain the left ventricle — which has been operating at low systemic resistance — to develop sufficient pressure and mass to sustain systemic afterload after arterial switch.
• FloWatch non-invasive adjustability: The transcutaneous adjustability of the FloWatch system avoids the morbidity of surgical revision for band tightening or loosening, reduces hospital admissions, and allows precise haemodynamic titration in response to the child's growth and physiological changes.

Pulmonary artery banding, while less complex than complete intracardiac repair, carries significant risks that must be understood by families and the multidisciplinary team.

• Band migration: The band may migrate distally towards the pulmonary valve or proximally towards the main pulmonary trunk, altering the degree of obstruction and potentially causing complications including pulmonary regurgitation. Migration risk is reduced by meticulous suture fixation of the band to the adventitia of the pulmonary artery, but remains a recognised complication particularly in growing infants.
• Supraaortic tethering: When PAB is performed via sternotomy, the band or its sutures may adhere to adjacent structures including the aorta, superior vena cava, or right ventricular outflow tract. This adhesion — "supraaortic tethering" — can distort great vessel geometry, cause obstruction, and complicate subsequent reoperation for complete repair.
• Excessive or inadequate banding: Over-tightening the band causes right ventricular hypertension, hypertrophy, and failure, and can cause acute haemodynamic collapse intraoperatively. Under-tightening fails to protect the pulmonary vasculature. The optimal target — main PA pressure approximately one-third to one-half systemic — requires precise intraoperative haemodynamic monitoring including direct pressure measurement and pulse oximetry.
• Residual PA deformity after debanding: Even after successful debanding at the time of complete repair, the banded segment of the pulmonary artery may have developed hypoplasia, stenosis, or distortion requiring patch augmentation. Branch pulmonary artery stenosis after hybrid Stage I bilateral PAB is a well-recognised complication requiring catheter intervention or surgical arterioplasty at Stage II.
• Inter-stage mortality: For single-ventricle patients, the inter-stage period between PAB and the Glenn anastomosis carries significant mortality risk (5–15% in some series), particularly due to interstage haemodynamic deterioration, acute shunt thrombosis, or intercurrent respiratory illness. Close surveillance with home saturation monitoring programmes reduces but does not eliminate this risk.
• Wound and thoracotomy complications: Standard surgical risks including bleeding, chylothorax, phrenic or recurrent laryngeal nerve injury, and wound infection apply.

Following pulmonary artery banding, structured surveillance is critical to monitor band function, track haemodynamic evolution, and plan the timing of the definitive repair.

• Immediate postoperative intensive care: Infants are managed in a specialist paediatric cardiac intensive care unit (PCICU). Continuous invasive monitoring includes arterial and central venous pressure lines. Target saturations of 80–85% are maintained in single-ventricle physiology. Echocardiography is performed within 24 hours to confirm band position, pressure gradient across the band, and ventricular function.
• Serial echocardiographic surveillance: Fortnightly to monthly echocardiograms assess the trans-band pressure gradient (target 40–60 mmHg in biventricular repairs, lower in single-ventricle cases), pulmonary artery anatomy, and ventricular dimensions and function. The FloWatch device status is checked at each visit if used.
• Cardiac catheterisation before definitive repair: Pre-operative cardiac catheterisation at 3–6 months of age assesses pulmonary artery anatomy, branch PA pressures, pulmonary vascular resistance (PVR), and suitability for complete repair. PVR must be below 3–4 Wood units/m² for safe biventricular repair or Fontan completion.
• Interstage monitoring for single-ventricle patients: Home pulse oximetry programmes with threshold alerts (SpO2 below 70% or weight gain failure) are used in many centres to detect inter-stage haemodynamic deterioration early, allowing prompt readmission and intervention before catastrophic deterioration.
• Definitive repair planning: For VSD and AVSD patients, complete repair is typically planned at 3–6 months post-banding once the infant has achieved 5–6 kg, pulmonary vascular resistance is acceptable, and anatomy has been fully characterised. For single-ventricle patients, the Glenn anastomosis (bidirectional cavo-pulmonary connection) is planned at 3–6 months of age.

Pulmonary artery banding is a specialist neonatal and infant cardiac surgical procedure performed exclusively in paediatric cardiac surgery centres with appropriate intensive care infrastructure. Costs reflect the complexity of care, ICU requirements, and the anticipated staged surgical pathway.

• United Kingdom (NHS): PAB and subsequent complete repair are fully NHS-funded at designated paediatric cardiac surgical centres (there are 13 such centres in England and Wales). Private paediatric cardiac surgery is uncommon in the UK; when undertaken, the surgical episode alone may cost £15,000–£30,000 excluding ICU and nursing care.
• India: India has world-class paediatric cardiac surgical programmes at AIIMS Delhi, Narayana Hrudayalaya (Bengaluru), Amrita Institute (Kochi), and multiple other centres. Combined PAB and subsequent repair costs range from USD 4,000–10,000 — a fraction of costs in Western countries. Charitable programmes (e.g., Gift of Life, Rotary) provide subsidised or free surgery for eligible families.
• United States: Neonatal and infant cardiac surgery at a US academic centre may cost USD 50,000–150,000 per procedure including ICU care; multiple staged procedures substantially increase the total episode cost. Insurance coverage under CHIP (Children's Health Insurance Programme) and Medicaid applies for eligible children.
• Germany, Singapore, and Thailand: Centres of excellence offering international paediatric cardiac surgery at USD 15,000–40,000 per staged procedure, with established pathways for international paediatric patients.
• FloWatch device cost: The FloWatch-PAB system carries a device cost (approximately USD 5,000–8,000) in addition to the operative costs, but may reduce total episode costs by avoiding surgical revision for band adjustment.

For families seeking international care for complex congenital heart disease, verification of the centre's volume of PAB and staged repair cases, paediatric intensivist availability, and outcomes data is essential before proceeding.

In many cases, advances in neonatal cardiac surgery have allowed primary complete repair to replace PAB as the preferred strategy. However, several situations continue to justify PAB or alternative approaches.

• Primary complete repair without banding: For most large VSDs in infants above 3 kg without additional comorbidities, direct intracardiac repair under cardiopulmonary bypass at 3–6 months of age is now the standard of care in high-volume centres, avoiding the two-stage approach entirely. Similarly, complete AVSD repair is performed at 3–6 months in most specialist centres without prior PAB.
• Norwood Stage I procedure for HLHS (alternative to hybrid): The classic surgical approach for hypoplastic left heart syndrome, performing single-ventricle palliation with neo-aortic reconstruction, systemic-to-pulmonary shunt, and atrial septectomy under cardiopulmonary bypass in the neonatal period. The hybrid alternative using bilateral PAB + ductal stenting avoids neonatal bypass but defers that haemodynamic challenge to the comprehensive Stage II. Choice depends on institutional experience and specific cardiac anatomy.
• Catheter-based device closure of VSD: For anatomically suitable muscular or perimembranous VSDs, transcatheter closure using an Amplatzer or equivalent device avoids surgery entirely. This option is limited by defect anatomy, patient size, and proximity to valvar structures, but represents a non-surgical alternative for selected lesions.
• Medical management and optimisation: Aggressive management of pulmonary overcirculation with diuretics (furosemide, spironolactone), ACE inhibitors (captopril), and nutritional support via nasogastric or gastrostomy feeding may allow an infant with a borderline indication for PAB to gain sufficient weight and stability for primary complete repair without banding.
• Compassionate or comfort care: In cases of extremely complex multiorgan disease, chromosomal anomalies with very poor prognosis, or family preference, surgical palliation may not be pursued. This decision involves the full multidisciplinary team, cardiac ethics consultation, and family-centred decision-making.

Each decision about PAB versus primary repair versus alternative strategy requires individualised assessment by an experienced paediatric cardiac surgical team at a high-volume congenital heart disease centre.